Physician profile
John E Vandruff
NPI 1700885563
$1,007.84
in general payments reported to CMS, 2019-2025
23 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $108 · 2021: $47.25 · 2022: $12.06 · 2023: $159 · 2024: $235 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $134.27 | 2019-2025 | |
| Pfizer INC. | $113.32 | 2019-2024 | |
| Abbott Laboratories | $95.47 | 2024 | Aveir |
| Allergan, INC. | $84.07 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $73.94 | 2019-2024 | Breztri |
| Glaxosmithkline, LLC. | $57.42 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $54.29 | 2020-2021 | |
| Medtronic, INC. | $45.86 | 2025 | Minimed 780g |
| Abbvie INC. | $37.44 | 2019-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $35.30 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $34.29 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $27.37 | 2023 | Rexulti |
| Octapharma USA, INC. | $25.02 | 2025 | Panzyga |
| Merck Sharp & Dohme LLC | $24.51 | 2019-2020 | |
| Novo Nordisk INC | $20.86 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $20.37 | 2024 | Gamunex-C |
| Aimmune Therapeutics, INC. | $20.13 | 2025 | Zenpep |
| Astellas Pharma US INC | $20.03 | 2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.03 | 2019 | |
| Biogen, INC. | $18.45 | 2023 | Skyclarys |
| Exact Sciences Corporation | $17.52 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.00 | 2023 | Quviviq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.88 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vandruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.